QuidelOrtho Corporation (0A55)
Summary
QuidelOrtho: Too Much Uncertainty Around Earnings Keeping Short-Interest Elevated
QuidelOrtho Corporation continues its steep decline, with over 40% losses since February and a $5B market cap drop since its 2022 merger. QDEL's Q4 and Q1 results both disappointed, with 2026 EPS guidance cut twice in three months and consensus now at $1.85 per share. Profitability struggles are compounded by rising debt, high inventory, weak Chinese sales, and a soft respiratory season, with no clear mitigation strategies outlined.
QuidelOrtho (QDEL) Moves 32.2% Higher: Will This Strength Last?
QuidelOrtho (QDEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
QDEL's strong portfolio, cost-saving progress and mixed first-quarter results support growth, though respiratory reliance remains a risk.
QuidelOrtho Corporation (0A55) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has QuidelOrtho Corporation ever had a stock split?
QuidelOrtho Corporation Profile
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Brian J. Blaser CEO | LSE Exchange | 219798105 CUSIP |
| US Country | 6,600 Employees | - Last Dividend | - Last Split | 1 Feb 1991 IPO Date |
Overview
QuidelOrtho Corporation specializes in providing a wide range of diagnostic testing solutions aimed at enhancing patient care and health management. The company organizes its operations through four main business units: Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics, each focused on delivering innovative testing products and instrumentation across various healthcare settings. Established in 1979 and based in San Diego, California, QuidelOrtho has a global footprint, serving customers in North America, Europe, the Middle East, Africa, and China. The company leverages a mix of direct sales and distributor networks to reach its diverse customer base, which includes physician offices, hospitals, clinical laboratories, blood banks, and more, catering to both professional and over-the-counter diagnostic needs.
Products and Services
- Labs Business Unit
This division offers a comprehensive array of clinical chemistry laboratory instruments and tests for measuring bodily fluid chemicals pertinent to patient health evaluation and clinical management. It also provides immunoassay laboratory instruments and tests for detecting proteins associated with disease spread, immune responses, or organ function markers. Furthermore, the unit supplies specialized diagnostic solutions across various therapeutic areas to assist in disease detection and monitoring.
- Transfusion Medicine Business Unit
Specializing in ensuring safe blood transfusions, this unit produces immunohematology instruments and tests vital for blood typing and patient-donor compatibility. It also encompasses donor screening instruments and tests for identifying infectious diseases in blood and plasma donations, crucial for maintaining a safe blood supply.
- Point-of-Care Business Unit
This segment focuses on delivering rapid test results through instruments and tests designed for a range of point-of-care settings. These solutions are pivotal in making immediate clinical decisions, enhancing patient convenience and care quality by providing timely diagnostic information.
- Molecular Diagnostics Business Unit
At the forefront of molecular diagnostic technologies, this business unit offers advanced systems like polymerase chain reaction (PCR) thermocyclers, amplification systems, and sample-to-result molecular instruments. These products are targeted at syndromic infectious disease diagnostics, offering precise and rapid identification of pathogens to facilitate effective treatment planning.
